Language: BG BG
← Back to results
Recruiting Phase 3 NCT03893045

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Phase 3 – large-scale trial before approval
Conditions: Iron Deficiency Anemia

Sponsor: AMAG Pharmaceuticals, Inc.

trial.available_in: БГ
Overview
This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology, except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol protocol).
Description
Subjects will be randomized to treatment in a 2:1 ratio (ferumoxytol: iron sucrose) and stratified by age group (2 to \<6 years; 6 to \<12 years; and 12 to \<18 years). Subjects will receive one of the following treatment regimens: • Ferumoxytol: 7 mg Fe/kg IV (maximum 510 mg/dose) x 2 doses, the first dose administered on Day 1 and the second 2 to 8 days later. OR • Iron sucrose (Venofer®): 4 mg Fe/kg IV (maximum 200 mg/dose) x 5 doses, the first dose on Day 1 and subsequent doses administered at least once per week and up to 3 times/week. All subjects will be monitored at the study site through at least 1 hour after the completion of each infusion of study drug. Assessment of blood Hgb concentrations, adverse events, and other safety assessments will be performed through study Week 5.
Who can participate
Inclusion Criteria: 1. Male or female 2 years to \<18 years of age at time of consent 2. Has IDA defined as: 1. Hemoglobin (Hgb) \<11.0 g/dL AND 2. Any one or more of the following: * Transferrin saturation (TSAT) \<20% * ferritin \<100 ng/mL 3. Documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate Exclusion Criteria: 1. Known hypersensitivity reaction to any component of ferumoxytol or iron sucrose 2. History of allergy to intravenous (IV) iron 3. History of ≥2 clinically significant drug allergies 4. Subjects with CKD (defined as eGFR of \<60 mL/min/1.73 m2 or a requirement for chronic hemodialysis or peritoneal dialysis during Screening) 5. Low systolic blood pressure (BP) (age 1 to 9 years \<70 + \[age in years x 2\] mmHg, age 10 to 17 years \<90 mmHg) 6. Hgb ≤7.0 g/dL 7. Serum ferritin level \>600 ng/mL
Interventions
ferumoxytol
DRUG
Iron sucrose
DRUG
Locations 15
Lithuania (3)
JSC Saules seimos medicinos centras
Kaunas
NOT_YET_RECRUITING
Klaipeda Children's Hospital
Klaipėda
NOT_YET_RECRUITING
Children's Hospital-Affiliate of Vilnius University Hospital Santariskiu Klinikos
Vilnius
NOT_YET_RECRUITING
Poland (6)
Osrodek Badan Klinicznych In Vivo sp. z o.o.
Bydgoszcz
NOT_YET_RECRUITING
Prywatny Gabinet Lekarski Dr N. med. Jerzy Brzostek
Dębica
NOT_YET_RECRUITING
Pro Familia Altera Sp. z o.o.
Katowice
NOT_YET_RECRUITING
Korczowski Bartosz, Gabinet Lekarski
Rzeszów
NOT_YET_RECRUITING
Centrum Zdrowia MDM
Warsaw
NOT_YET_RECRUITING
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroclaw
NOT_YET_RECRUITING
United States (6)
Gwinnett Research Institute
Buford , Georgia
NOT_YET_RECRUITING
University of Florida
Gainesville , Florida
NOT_YET_RECRUITING
Arkansas Children's Hospital
Little Rock , Arkansas
NOT_YET_RECRUITING
Optimus U Corporation
Miami , Florida
Biomedical Research LLC
Miami , Florida
Sun Research Institute
San Antonio , Texas
Technical details
Status
Recruiting
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
2 Years
Maximum age
17 Years
Healthy volunteers
No
Start date
18.09.2019
Completion date
01.10.2026
Registry ID
NCT03893045
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.